Translational Oncology · 2019 · 20 citations · 33 references
MedicineEndocrinologyOncologyMetastasisTumor MicroenvironmentTumor ProgressionCancer Molecular PathologyCancer ProgressionCancer Survival AnalysisColorectal CancerDiabetes MellitusMalignant NeoplasmsAdenocarcinoma PathologyCancer Risk AssessmentColorectal Cancer PathologyColorectal Cancer PrognosisMetabolic Alterations In CancerTnm Staging SystemTumor Grade ClassificationTumor Microenvironment Effects
BACKGROUND: Diabetes mellitus is unfavorably associated with cancer risk. The purpose of this multidisciplinary project was to evaluate a possible association of diabetes mellitus and other comorbidities and their treatment with progression of colorectal cancer. PATIENTS AND METHODS: We investigated the correlation between pathological characteristics and clinical course, including comorbidities in 1004 Czech patients diagnosed and surgically treated for colorectal adenocarcinoma (CRC) between 1999 and 2016. RESULTS: In our data set, CRC patients treated with metformin due to coexisting diabetes mellitus type 2 (T2DM) developed fewer distant metastases which clinically correlates with slower CRC progression. Survival in metformin subgroup was longer, particularly in men with CRC. Osteoporosis may be a negative factor of survival in CRC patients. CONCLUSIONS: Our findings also indicate that aging, higher tumor grade and TNM stage, coexistence of selected endocrine disorders, and metabolic abnormalities may change the tumor microenvironment and impact survival in colorectal cancer, although mechanism of these observations yet to be explained. Patients with diabetes mellitus type 2 treated with metformin may represent the altered microenvironment with specifically tuned metabolic molecular responses and with various epigenetic characteristics. More awareness and increased understanding of the mechanisms underlying the positive effect of metformin on patients' survival could offer insight into new treatment methods and permit more individualized treatment plans.
33
Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy
Garnet L. Anderson, Marian C. Limacher, Annlouise R. Assaf et al. · JAMA · 2004 · 4.5K citations · Full text
Medicine, Endocrinology, Gynecology +13
Metformin and reduced risk of cancer in diabetic patients
Josie Evans, Louise A. Donnelly, Alistair Emslie‐Smith et al. · BMJ · 2005 · 2.4K citations · Full text
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
C. J. Currie, C Poole, E.A.M. Gale · Diabetologia · 2009 · 1.1K citations · Full text
Medicine, Oncology, Pharmacotherapy +13
Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status
Amy Cameron, Vicky L. Morrison, Daniel L. Levin et al. · Circulation Research · 2016 · 721 citations · Full text
Antidiabetic Therapies Affect Risk of Pancreatic Cancer
Donghui Li, Sai‐Ching J. Yeung, Manal M. Hassan et al. · Gastroenterology · 2009 · 580 citations · Full text
Medicine, Endocrinology, Oncology +12